Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

Sam K. Bouchillon, Jonathan R. Iredell, Timothy Barkham, Kyungwon Lee, Michael J. Dowzicky

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.

Original languageEnglish
Pages (from-to)130-136
Number of pages7
JournalInternational Journal of Antimicrobial Agents
Volume33
Issue number2
DOIs
Publication statusPublished - 2009 Feb 1

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)'. Together they form a unique fingerprint.

  • Cite this